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E-mail address: h.w.vandijk@amc.nl (H.W. van DijDiabetic retinopathy (DR) classically presents with micro-aneurysms, small haemorrhages and/or
lipoprotein exudates. Several studies have indicated that neural loss occurs in DR even before vascular
damage can be observed. This study evaluated the possible relationship between structure (spectral
domain–optical coherence tomography) and function (Rarebit visual ﬁeld test) in patients with type 1
diabetes mellitus and no or minimal diabetic retinopathy (DR). Results demonstrated loss of macular
visual function and corresponding thinning of the ganglion cell layer (GCL) in the pericentral area of
the macula of diabetic patients (Rs = 0.65, p < 0.001). In multivariable logistic regression analysis, GCL
thickness remained an independent predictor of decreased visual function (OR 1.5, 95% CI 1.1–2.1). Early
DR seems to include a neurodegenerative component.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
One of the most frequent causes of blindness among adults in
the Western world is diabetic retinopathy (DR) (Fong et al., 2004).
The clinical hallmarks of DR are primarily vascular, including mi-
cro-aneurysms, hemorrhages, capillary occlusions, and lipoprotein
exudates. In addition to vascular changes, neurodegenerative
changes have been described including neural apoptosis, loss of
ganglion cell bodies, glial reactivity and reduction in thickness of
the inner retinal layers in the earliest stages of DR (Abu-El-Asrar,
Dralands, Missotten, Al-Jadaan, & Geboes, 2004; Antonetti et al.,
2006; Barber, 2003; Barber et al., 1998, 2005; Gardner, Antonetti,
Barber, LaNoue, & Levison, 2002; Gastinger, Kunselman, Conboy,
Bronson, & Barber, 2008; Gastinger, Singh, & Barber, 2006; Kern &
Barber, 2008; Li & Puro, 2002; Martin, Roon, Van Ells, Ganapathy,
& Smith, 2004; Park et al., 2003; Rungger-Brandle, Dosso, & Leuen-
berger, 2000). These ﬁndings of structural neuropathy may explain
the neuroretinal functional deﬁcits that are known in patients with
diabetes, even before the presence of frank retinopathy. Several
studies have shown electro-retinogram abnormalities, loss of darkll rights reserved.
f Ophthalmology, Academic
, The Netherlands. Fax: +31
k).adaptation and contrast sensitivity and color vision disturbances
independent of vascular retinopathy (Bearse, et al., 2006; Bron-
son-Castain et al., 2009; Di Leo et al., 1992; Dosso et al., 1996;
Hardy, Lipton, Scase, Foster, & Scarpello, 1992; Kurtenbach, Flogel,
& Erb, 2002; Lopes de Faria, Katsumi, Cagliero, Nathan, & Hirose,
2001; Ng, Bearse, Schneck, Barez, & Adams, 2008; Realini, Lai, & Bar-
ber, 2004).
Conventional threshold perimetry and visual function tests are
insensitive measures of minor neuro-visual damage (Frisen &
Quigley, 1984; Kerrigan-Baumrind, Quigley, Pease, Kerrigan, &
Mitchell, 2000). The Rarebit technique, which includes Rarebit
Perimetry (RBP) and the Rarebit Fovea Test (RFT), was developed
to improve detection of subtle defects (Frisen, 2002). The Rarebit
technique is based on the principle of detection of very small and
bright stimuli. The small stimulus corresponds to half the mini-
mum angle of resolution at the tested retinal location. The test
avoids simultaneous stimulation of more than one receptive ﬁeld,
deﬁned as the group of photoreceptors converging on the same
ganglion cell (Fischer, 1973). In a previous study employing the
Rarebit technique, Nilsson et al. detected foveal dysfunction in pa-
tients with diabetes mellitus type 1 without DR (Nilsson, Von,
Wanger, & Martin, 2007).
With optical coherence tomography (OCT) the retinal thickness
(RT) can be measured with high accuracy. The retinal thickness in
diabetic patients with no or minimal DR is thinner than in normals.
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et al., 2007; Bronson-Castain et al., 2009; Browning, Fraser, & Clark,
2008; Nilsson et al., 2007; Oshitari, Hanawa, & Adachi-Usami,
2009; Van Dijk et al., 2009). The high resolution of spectral do-
main–OCT (SD–OCT) allows measurement of the thickness of all
individual retinal layers (Garvin et al., 2008), especially if the layers
are segmented automatically in three-dimensions (Garvin et al.,
2009). Results of a recent study showed that the decreased total
RT in type 1 diabetic patients with minimal DR is predominantly
caused by a thinning of the ganglion cell layer (GCL) in the pericen-
tral area and retinal nerve ﬁber layer (RNFL) thinning in the periph-
eral area of the of the macula (Van Dijk et al., 2010), i.e. both axons
and nerve bodies are involved in thinning.
The purpose of the present study is to evaluate the hypothesis
that GCL thickness measured with SD–OCT and the function of
the macula tested with the Rarebit technique are associated in pa-
tients with type1 diabetes mellitus (DM) and no or minimal DR.2. Materials and methods
2.1. Patients
Patients with type 1 DM were recruited from the outpatient
clinic of the department of Internal Medicine at the Academic Med-
ical Center (AMC University Hospital, Amsterdam, The Nether-
lands) for an ongoing longitudinal observational study. In
September 2008 they were invited to participate in this observa-
tional cross-sectional study. Additionally, healthy age-matched
individuals served as controls. The study adhered to the tenets of
the Declaration of Helsinki, and Institutional Review Board ap-
proval was obtained at both the AMC and the University of Iowa.
All subjects provided written informed consent.
DR status was evaluated by a retinal specialist through indirect
fundoscopy, slit-lamp stereo biomicroscopy and stereoscopic fun-
dus photography. Patients were included if they were diagnosed
with minimal or no DR. The deﬁnition of minimal DR was conform
stage 2 of the International Clinical Diabetic Retinopathy Disease
Severity Scale (Wilkinson et al., 2003). Control subjects did not
have a diagnosis of any ocular disease, diabetes or other systemic
disease, and were randomly recruited from accompanying persons
of patients visiting the outpatient clinic of the department of Oph-
thalmology. Exclusion criteria were refractive errors over S+5, or
under S8 diopters, visual acuity below 20/25, signiﬁcant media
opacities, previous ocular surgery and a previous diagnosis of glau-
coma, uveitis, or retinal disease.
Age, gender, duration since diagnosis of diabetes and serum gly-
cosylated hemoglobin (HbA1c) at the time of the study examina-
tions were gathered from the patient charts. Best corrected visual
acuity was obtained conform the Early Treatment Diabetic Reti-
nopathy Study, and recorded as Snellen equivalent. All subjects
underwent Rarebit Perimetry and the Rarebit Fovea Test (Frisen,
2002). Finally, all subjects underwent papillary dilatation and an
ophthalmic examination including slitlamp biomicroscopy with a
handheld lens (SuperField; Volk Optical, Inc., Mentor, OH), OCT
imaging (3D OCT-1000, Topcon Corporation, Tokyo, Japan) and ste-
reoscopic fundus photography (TRC-50IX; Topcon Corporation, To-
kyo, Japan).2.2. Rarebit perimetry and Rarebit Fovea Test
The RBP and the RFT form a computerized visual function test
developed to detect subtle damage to the visual system (Frisen,
2002). The RBP evaluates the central 30 visual ﬁeld, while the
RFT evaluates the central 4 visual ﬁeld. The test principle is to
brieﬂy (200 ms) present zero, one, or two, bright small (<0.5 minof arc) dots against a dark background in a completely dark room.
Due to photopic luminance levels for both the ﬁxation mark and
the test targets, dark adaptation is not of inﬂuence for test results.
The subjects are asked to focus on the ﬁxation mark and mean-
while respond by clicking a mouse button once or twice when they
detect one respectively two dots anywhere on the screen. The re-
sult of the Rarebit test is presented as mean hit rate (MHR). The
MHR is a percentage of the stimuli seen by the subject of all pre-
sented stimuli. In this study we combined the RFT and RBP and
present a combined MHR. The combined MHR is abnormal if below
95% (Malmer & Martin, 2005; Salvetat, Zeppieri, Parisi, & Brusini,
2007).2.3. Optical coherence tomography imaging and layer segmentation
OCT images of the subjects were obtained with SD–OCT (3D
OCT-1000, Topcon Corporation, Tokyo, Japan) using the 3D volume
scan protocol (6  6  2.2 mm3), consisting of 128 (y) by 512 (x) by
650 (z) voxels. From this volume, nine intraretinal surfaces deﬁn-
ing eight retinal layers were segmented automatically by our algo-
rithm, which uses an extensively validated, robust fully three-
dimensional graph search approach (Garvin et al., 2009). The eight
layers were interpreted as follows (from inner to outer surface): 1/
retinal nerve ﬁber layer (RNFL), 2/ganglion cell layer (GCL), 3/inner
plexiform layer (IPL), 4/inner nuclear layer (INL), 5/outer plexiform
layer (OPL), 6/outer nuclear layer (ONL) + inner segments (photo-
receptors) (IS), 7/outer segments (photoreceptors) (OS), 8/retinal
pigment epithelium (RPE) (Fig. 1).
The pericentral area of the macula – a donut shaped ring cen-
tered on the fovea with an inner diameter of 1 mm – was deﬁned
by one of the authors (HvD), who was masked for the DR status and
demographic features of the patients and controls. The mean thick-
ness of each layer in the pericentral area was automatically calcu-
lated with the computer program ImageJ 1.41 (Abràmoff,
Magalhâes, & Ram, 2004).2.4. Statistical analysis
For the statistical analyses SPSS 16.0.2 for Windows (SPSS, Chi-
cago, IL) was used. An independent t-test was used to assess differ-
ences in mean age and MHR between diabetic patients and
controls. A Chi-square test was used to compare distribution of
gender between patients and controls. Mean HbA1c, age, duration
of diabetes and mean pericentral GCL thickness of diabetic patients
with subnormal MHR and diabetic patients with normal MHR were
compared using the independent t-test. The presence or absence of
DR was compared between patients with subnormal and normal
MHR using the Chi-square test. The possible correlation between
MHR and pericentral GCL and INL thickness was analyzed using
the Spearman rank test. Multivariable logistic regression analyses
were performed to identify independent predictors of subnormal
MHR. Conﬁdence intervals were computed at the p = 0.05 level.3. Results
Thirty-two patients type 1 diabetes with no or minimal DR and
38 controls were included. There was no signiﬁcant difference in
age and gender between patient groups and controls (see Table 1).
Patients were in reasonable glycemic control (mean HbA1c = 8.1%;
SD = 1.4).
The mean MHR of patients with DM and controls were
93.5 ± 5.3 and 97.1 ± 2.8, respectively. The mean MHR of the pa-
tient group was signiﬁcantly decreased compared with the control
group (95% CI of the difference 1.6–5.6).
Fig. 1. The intraretinal surfaces in a macular B-scan as indicated by the colored lines and the corresponding retinal layers in ﬁgures. The retinal surfaces are segmented fully
automatically using an inherently 3D approach. 1/retinal nerve ﬁber layer, 2/ganglion cell layer, 3/inner plexiform layer, 4/inner nuclear layer, 5/outer plexiform layer, 6/outer
nuclear layer + inner segments, 7/outer segments, 8/retinal pigment epithelium.
Table 1
Demographics of patients with type 1 diabetes and controls.
Parameters DM (n = 32) Controls (n = 38)
Age (years) 34 ± 10 35 ± 11
Gender (M:F) 12:20 19:19
HbA1c (%) 8.1 ± 1.4 –
Values are the mean ± standard deviation for all subjects in each group. DM, dia-
betes mellitus; –, not performed; F, female; HbA1c, glycosylated hemoglobin; M,
male.
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duration of DM and were older than subjects with normal MHR
(see Table 2). HbA1c did not differ signiﬁcantly between the
groups. Although the number of subjects with minimal DR differed
substantially between the patient group with subnormal MHR and
normal MHR this difference was not signiﬁcant (Chi-square,
p = 0.08). The patients with subnormal MHR had signiﬁcantly low-
er pericentral GCL and INL thickness (see Table 3). The remaining
retinal layers did not differ signiﬁcantly between patients with
normal and subnormal MHR.
In the population of 32 DM patients, both the pericentral GCL
thickness (Rs = 0.65, p < 0.001) and the pericentral INL thickness
(Rs = 0.41, p = 0.02) showed a signiﬁcant correlation with the
MHR. However in logistic regression analysis with GCL and INL
thickness as variables, the GCL thickness was the strongest inde-
pendent predictor of subnormal MHR (OR 1.37, 95% CI 1.05–1.79)
compared to the INL thickness (OR 0.99, 95% CI 0.72–1.37). Subse-
quently the GCL thickness remained the only independent predic-
tor of subnormal MHR (OR 1.5, 95% CI 1.1–2.1) in a second
multivariable logistic regression analysis with GCL thickness, dura-
tion of DM, DR status, HbA1c and age as variables. Duration of DM
(OR 1.0, 95% CI 0.8–1.1), DR status (OR 0.7, 95% CI 0.04–10.9),
HbA1c (OR 2.5, 95% CI 0.8–7.6) and age (OR 0.9, 95% CI 0.8–1.0)
had no predictive value for subnormal MHR. A scatter-plot of
GCL thickness versus MHR is shown in Fig. 2.Table 2
Duration of diabetes, age, HbA1c and retinopathy status in patients with type 1
diabetes with subnormal MHR compared to patients with normal MHR.
Parameters Subnormal
Rarebit
(n = 14)
Normal
Rarebit
(n = 18)
Mean
difference
95% CI of the
difference
Lower Upper
Duration of DM (years) 24.6 ± 9.9 16.7 ± 5.3 7.9 2.3 13.4
Age (years) 39.8 ± 9.3 30.1 ± 7.9 9.6 3.4 15.8
HbA1c (%) 7.8 ± 1.3 8.4 ± 1.5 0.59 1.6 0.5
Minimal DR (%) 64% 33% NA NA NA
Values are the mean ± standard deviation. CI, conﬁdence interval; DM, diabetes
mellitus; DR, diabetic retinopathy; HbA1c, glycosylated hemoglobin; MHR, mean
hit rate; NA, not applicable.4. Discussion
These results support our hypothesis that GCL thickness as
measured with SD–OCT and the macular sensitivity as tested with
the Rarebit technique are associated. In fact, decreased GCL thick-
ness in the pericentral area of the macula correlates highly with
MHR, and is the only signiﬁcant predictor of subnormal MHR, inde-
pendent of other known variables. To our knowledge, this study is
the ﬁrst to describe the possible link between structure and func-
tion in type 1 diabetes patients.
The results support the early neurodegenerative effect of diabe-
tes on the retina. The ganglion cells seem to be most vulnerable to
diabetes related degeneration (Abu-El-Asrar et al., 2004; Antonetti
et al., 2006; Barber, 2003; Barber et al., 1998; Gardner et al., 2002;
Gastinger et al., 2008; Kern & Barber, 2008;Martin et al., 2004). This
study shows a decreased MHR in diabetes patients due to loss of
receptive ﬁelds which is possibly caused by apoptosis of ganglion
cells throughout the retina. However, the question remainswhether
the function decrease is directly and solely caused by the ganglion
cell lossorwhether theganglioncell loss is aproxy for amoregeneral
neuronal loss. In this study the INL was also signiﬁcantly decreased
in thickness. All retinal neurons - photoreceptors, bipolar cells, hor-
izontal cells, amacrine cells and ganglion cells – are involved in the
transmissionof visual signals to thebrain (Masland, 2001).Degener-
ation of the neuroretinal system is associated with architectural de-
fects such as loss or disconnection of retinal ganglion cells or
upstreamconnections. The results of the Rarebit test in type 1diabe-
tes patients indicate that such architectural defectsmayproduce the
small visual ﬁeld defects as observed in this study (Frisen, 2002).
Both foveal dysfunction and GCL thinning in patients with type
1 diabetes have been described previously (Nilsson et al., 2007;
Van Dijk et al., 2009, 2010). In glaucoma, previous studies at-
tempted to understand how functional losses may relate to struc-
tural damage. Glaucoma is an optic neuropathy characterized by a
loss of retinal ganglion cells leading to characteristic changes in the
structure of the optic disc and in loss of visual ﬁelds, as measured
with standard automated perimetry. Recent studies detected mac-
ular thinning of the ganglion cell layer in glaucoma patients using
SD–OCT. The location of ganglion cell loss colocalized with the vi-
sual ﬁeld loss. The most severe loss of ganglion cells was seen in
patients with the most severe loss of visual ﬁeld loss. Signiﬁcant
thinning of the GCL could be detected in pre-perimetric glaucoma
patients. These studies conﬁrm the relationship between structural
loss of ganglion cells and functional loss (Hood & Kardon, 2007;
Strouthidis et al., 2006; Tan, Li, Lu, Varma, & Huang, 2008; Tan
et al., 2009; Wang et al., 2009). In patients with DM the loss of gan-
glion cells is much less pronounced, and in general will not lead to
frank visual ﬁeld loss. The Rarebit technique tests visual function
differently and is sensitive to local loss of single receptive ﬁelds.
The present study has some pitfalls. The grading of the severity
of DR was done by a single reader through ophthalmologic exam-
ination and evaluation of a single set of stereoscopic central retinal
Table 3
Mean layer thickness measurements (microns) of the individual intraretinal layers in
the pericentral area of the macula in patients with type 1 diabetes with subnormal
Rarebit MHR compared to patients with normal Rarebit MHR.
Parameters Subnormal
Rarebit
(n = 14)
Normal
Rarebit
(n = 18)
Mean
difference
95% CI of the difference
Lower Upper
RNFL 20.3 ± 1.8 21.4 ± 1.9 1.1 2.4 0.3
GCL 46.3 ± 5.4 54.5 ± 4.6 8.2 11.8 4.6
IPL 37.0 ± 4.4 38.1 ± 2.9 1.1 3.8 1.4
INL 37.3 ± 4.7 40.8 ± 3.4 3.5 6.4 0.6
OPL 29.9 ± 4.8 28.3 ± 2.7 1.6 1.1 4.4
ONL + IS 86.9 ± 13.0 93.3 ± 9.0 6.4 14.4 1.5
OS 27.2 ± 2.0 26.2 ± 1.7 1.0 0.2 2.4
RPE 38.6 ± 1.8 39.6 ± 1.4 1.0 2.1 0.2
Values are the mean ± standard deviation for all subjects in each group. The bold
values indicate a statistically signiﬁcant difference between patients with normal
and subnormal Rarebit Test. DR, diabetic retinopathy; CI, conﬁdence interval; MHR,
mean hit rate; RNFL, retinal nerve ﬁber layer; GCL, ganglion cell layer; IPL, inner
plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer
nuclear layer; IS, inner segments; OS, outer segments; RPE, retinal pigment
epithelium.
Fig. 2. Scatter-plot of pericentral GCL thickness versus MHR in type 1 diabetes
patients.
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scopic fundus photography assessment by independent trained
graders (Early Treatment Diabetic Retinopathy Study Research
Group, 1991). However, the patients deﬁnitely did not have ad-
vanced retinopathy, indicating that the results do apply to the ear-
liest stage of DR.
Type 2 diabetes is often subclinical. It cannot be excluded that
some controls actually had diabetes type 2 and elevated blood su-
gar levels because the HbA1c of the normal subjects was not
known. The prevalence of diabetes at this age is however low.
The presence of undiagnosed diabetes would most likely lead to
underestimation of the difference in retinal layer thickness be-
tween patients and controls instead of overestimation.
Furthermore, the number of included patients in this study is
low. Due to low power it can not be ruled out that some of the vari-
ables in the logistic regression model would have been signiﬁ-
cantly correlated with the decrease of MHR if the number of
patients was higher. In a previous study concerning GCL thinning
in diabetic patients, the presence of early vasculopathy was the
most important explanatory variable for the observed decrease in
GCL thickness. The same study showed that the duration of DM
was signiﬁcantly correlated with GCL thickness (Van Dijk et al.,2010). Studies by Nilsson et al. and Salvetat et al. both previously
showed that age correlated negatively with MHR (Nilsson, Wanger,
& Martin, 2006; Salvetat et al., 2007). However the fact that in this
study solely the GCL remains an independent predictor in the mul-
tivariable logistic regression model despite the small number of in-
cluded patients shows that the correlation between the GCL
thinning and the visual function is strong.
In summary, this study demonstrates subtle loss of macular vi-
sual function and corresponding loss of thickness of the GCL in the
pericentral area of the macula in type 1 diabetic patients. These re-
sults support the concept that early DR includes a neurodegenera-
tive component. Though larger studies are needed, the hypothesis
of diabetes causing a retinal neuropathy independent of vascular
retinopathy is intriguing, and potentially links retinal neuropathy
to other diabetic neuropathies.
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